Dr. Saad on Apalutamide Combination for Castration-Resistant Prostate Cancer
Fred Saad, MD
Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.
In a phase Ib study, abiraterone (Zytiga) plus apalutamide, also known as ARN-509, was investigated to determine the safety and efficacy of the combination. It is already known that abiraterone is extremely effective in improving the overall survival and delaying the progression of the disease, but the researchers wanted to determine the safety when adding apalutamide, Saad explains.
This study aimed to determine that the pharmacokinetics (PK) of both abiraterone and apaludtamide are not effected by each other. It was discovered that the addition of apalutamide did not affect the PK levels that are required to be efficacious.